Malaysian Market Community

Company Background An investment holding company, manufactures, trades in, and retails jewelry, bullion, precious and semi-precious stones, and gold ornaments primarily in Malaysia. Their product range includes gold bars, notes, and coins; rings, couple rings, bracelets, pendants, necklaces, bangles, and earrings; white and rose gold, diamonds, pearls, jades, and personalized and fine jewelry.

Company Background An investment holding company, operates in the property development and construction businesses in Malaysia and Fiji. The company is divided into three segments: Property Development, Construction, and Others.

In recent months, KJTS Group Berhad (KLSE: KJTS) has emerged as one of the more exciting small-cap growth stories on Bursa Malaysia. With a 106% share price surge over the past year and a 25% jump in just the last month, the market is starting to take notice – and rightfully so.

Tex Cycle Technology (M) Berhad-Bursa: 0089 (“Tex Cycle” or the “Company”) has been making significant strides in the waste management and environmental sustainability sector. The recent Technical Buy report by Public Bank on 12 Dec 2024 highlights the Company's robust momentum, with a current price of RM1.15 and target prices of RM1.21 and RM1.28, reflecting potential returns of 5.2% and 11.3% respectively.

Bintai Kinden Berhad (Bursa Malaysia: 6998), a prominent player in the engineering services sector of Malaysia. The company specialises in engineering services and has expanded its operations through various subsidiaries, including Kejuruteraan Bintai Kindenko Sdn Bhd and Johnson Medical International Sdn Bhd.

Catalysts 1. SSF Home Group Berhad (Bursa Malaysia: 0287) listed on the Bursa Malaysia 12 October 2023 2.

LYC Healthcare: Progress Amid Challenges LYC Healthcare’s latest Q2 FY2025 results reflect steady progress, with revenue rising 29% year-on-year to RM41.74 million from RM32.01 million. This growth was driven by strong performance in its nutraceutical, clinical, and confinement businesses, alongside contributions from new subsidiaries.

Sunzen Biotech Berhad: Q1 FY25 Financial Insights and Technical Outlook Financial Performance Overview Sunzen Biotech Berhad posted a stable financial performance for Q1 FY25, achieving a revenue of RM22.96 million, an 11.42% increase compared to the preceding quarter. Key contributors were: • Human Health Segment: RM17.65 million in revenue, driven by robust export sales of edible bird’s nests to China, constituting 79.32% of segment revenue.

28 November 2024 Catalysts 1. Hektar REIT (KLSE: 5121) portfolio of retail and education properties throughout Malaysia.